Robert E. Dupuis - Concepedia

Author

Robert E. Dupuis

University of North Carolina at Chapel Hill

Also Known As

Dupuis, Robert E., Hoefs, John C., James Cha, Persky, Adam M., R DUPUIS, R Dupuis, R E Dupuis, R. Dupuis, R. E. Dupuis, R.E Dupuis

Publications

2.6K

Citations

H-Index

Concepts

All Affiliations

University of North Carolina at Chapel Hill University of North Carolina Hospitals Leiden University Medical Center Medical University of South Carolina Brigham and Women's Hospital

About

Robert E. Dupuis is an author at University of North Carolina at Chapel Hill specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	15	826
2	Education	2	2	141
3	Health Sciences	2	2	303
4	Business	1	1	50
5	Natural Sciences	1	1	78

Robert E. Dupuis

Publications

Citations

H-Index

Page 1

	Year	Citations
Myocardial infarction patients in the 1990s—their risk factors, stratification and survival in Canada: The Canadian assessment of myocardial infarction (CAMI) study Jean L. Rouleau, Mario Talajic, Bruce Sussex, Journal of the American College of Cardiology Cardiovascular EpidemiologyHealth PolicyCardiovascular DiseaseHealth SciencesMyocardial Infarction	1996	267
Platelet Membrane Receptor Glycoprotein IIb/IIIa Antagonism in Unstable Angina Pierre Roux, Simon Kouz, Louis Roy, Circulation	1996	180
Depression and prognosis following hospital admission because of acute myocardial infarction. Claude Lauzon, Christine A. Beck, T. Huynh, PubMed	2003	168
The HOPE (Heart Outcomes Prevention Evaluation) Study: The design of a large, simple randomized trial of an angiotensin converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events F Mindlen, Roberto Nordaby, M I Soto Ruiz, Queensland's institutional digital repository (The University of Queensland) Non-pharmacological InterventionPreventive MedicineCardiovascular DiseaseAntihypertensive TherapyClinical Trials	1996	154
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab Emil Hagström, Philippe Gabríel Steg, Michael Szarek, Circulation	2022	112
Risk Stratification After Myocardial Infarction Using Signal-Averaged Electrocardiographic Criteria Adjusted for Sex, Age, and Myocardial Infarction Location P. Savard, Jean‐Lucien Rouleau, John G. Ferguson, Circulation	1997	104
Evolution of the Role of the Transplant Pharmacist on the Multidisciplinary Transplant Team Rita R. Alloway, Robert E. Dupuis, Steven Gabardi, American Journal of Transplantation TransplantationSolid Organ TransplantationTransplantation MedicineClinical PharmacyTransplant Pharmacist	2011	92
Use of Case-Based Learning in a Clinical Pharmacokinetics Course Robert E. Dupuis, Adam M. Persky American Journal of Pharmaceutical Education Case-based LearningClinical PharmacyEducationMedicinePharmaceutical Education	2008	91
Clinical Utility of C-Reactive Protein Measured at Admission, Hospital Discharge, and 1 Month Later to Predict Outcome in Patients With Acute Coronary Disease Peter Bogaty, L Boyer, Serge Simard, Journal of the American College of Cardiology Cardiovascular DiseaseClinical UtilityMyocardial InfarctionClinical EpidemiologyLaboratory Medicine	2008	87
The Influence of Norfloxacin and Metronidazole on the Disposition of Mycophenolate Mofetil Odin Naderer, Robert E. Dupuis, Erin L. Heinzen, The Journal of Clinical Pharmacology Healthy SubjectsPharmacotherapyDrug ResistanceMedicinal ChemistryMycophenolate Mofetil	2005	78

Page 1